February 2026 Pathology Update More Planned Changes

Recent Changes

• Raised BP in pregnancy – previously, our BP protocols were treating pregnant women in the same way as other patients. We’ve made changes now so that any raised BPs in pregnancy are flagged for immediate review with a clinician rather than being directed to home readings, etc. If average readings are being processed, the protocol will direct staff to arrange an urgent review that day.
• BPs needing urgent review – in our recent development of the prescribing module, our clinical governance committee raised concerns about patients needing urgent review based on information submitted on questionnaires. Whilst the questionnaires directed patients to contact the practice urgently where needed, we wanted to highlight those patients in clinical reports to ensure that actions were in hand. We’ve started to apply the same approach to BPs and have built reports to highlight patients who’ve either submitted a one-off reading, or have average home readings that need urgent review. This includes very high readings, or high readings in pregnancy. These are the reports we’ve built:

Pregnant patients with raised BP also won't be automatically sent requests for average readings. This may still be appropriate but we think these patients should be reviewed individually by a clinician to decide the appropriate course of action.

• AutoReview rules for FBC/LFT – we’ve now updated these rules to make them more robust and avoid any risk of results getting filed inappropriately because a lab is including investigations we’ve not accounted for. This is achieved by having more stages to the rules to reflect different ways that labs report the rules. If you’re finding that the rules aren’t working for your lab, please email support@welbyinnovate.co.uk with a screenshot of the investigations included in a result that you think should be AutoReviewed and we can update and test the rules to make sure those start filing for you.
• Indeterminate B12 results – A few practices are now using and testing our pathway for indeterminate B12 results. These are now being AutoReviewed and patients sent messages about possible symptoms that need further discussion. Let us know if you’d like to adopt this approach in your practice.

Planned Change

This weekend we’re planning to update all the labelling for our AutoReview rules. We want to make it clearer to understand how they work and group them together. This is the convention we’re going to follow - WI|Genre|Sub-genre|Lab (if applicable)|Battery name|Description of rule. e.g. “WI|Blood|HbA1c|HBA1C MONITORING|Files normal if no DM meds/if WIPath active other results will enter reports” or “WI|Blood|Satisfactory|Anti-cyclic citrullinated peptide antibody level (UoM Units) (Y11e0)|Files if lab report states Normal or <=ULN”. As well as making it easier to review and activate rules, it should make it clearer when reviewing AutoReview audits.